Takeda’s Max Access Solution Iclusig® (ponatinib) program donates the specialty care product, effective for the treatment of refractory chronic myeloid leukemia (CML) or Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL), to The Max Foundation to help cancer patients in low- and middle-income countries (LMICs), who would otherwise lack access to the drug due to unavailability in local markets. The Max Foundation channels Takeda’s Iclusig® (ponatinib) product to patients in need through their treating physicians and within the scope of its collaboration agreement. Vetted healthcare providers (HCP) in LMICs initiate the product request and manage the treatment of patients receiving the product from The Max Foundation. The Foundation works through a third-party logistics provider (3PL) who, as its agent, receives the product from manufacturers and ships it to end users on the organization’s behalf.
The Max Access Solution Iclusig® (ponatinib) program is especially critical to CML patients for whom other treatments have proven ineffective and for those who have T315I-positive CML or Ph+ ALL. As the program continues to grow, Takeda in collaboration with the Foundation are exploring ways to better support partner physicians on the use of the treatment, as well as to provide wrap-around support in areas such as diagnostics and adherence support.
for more information